Natural killer (NK) cells are large granular lymphocytes (LGL), that express cytolytic activity in vitro against various tumor cells, virally infected cells, and some microorganisms (1-3). They do not productively rearrange TCR genes (4-6), do not express CD3 (7), and are capable of lysing target cells without major histocompatibility restriction (8, 9) or previous antigen sensitization (10, 11). Extensive evidence indicates that NK cells are responsible for rejection of certain implanted syngeneic tumors and inhibition of certain experimental tumor metastasis (12-15).
of which 3 mg/ml was shown to be monoclonal IgGl) in 1 ml of HBSS once a day for 1-3 d. Control animals received injections of ascites fluid containing irrelevant IgGl antibody or purified irrelevant IgG1 antibody each diluted in HBSS. In tumor challenge experiments, animals were treated with one dose of 100 1tl of mAb 3.2 .3 ascites intraperitoneally and 3 d later were injected with 1.5 x 106 MADB106 cells intravenously or 5 x 106 MADB106 cells subcutaneously. In one experiment animals were pretreated for three consecutive days with 50 pg/ml affinity-purified 3.2.3 intraperitoneally and 1 d later were injected intravenously with 0.5 x 106 MADB106 cells . In vivo growth of subcutaneous tumors was measured over a period of 30 d with Vernier calipers measuring 2 diameters at right angles.
Statistics. For survival experiments, Kaplan-Meer curves were drawn and the differences in survival between the various groups was assessed using the generalized Savage (MantelCox) log-rank test. For statistical analysis ofblood differential counts the Mann-Whitney and the Student's t-test were used. All other statistical analysis was performed using the Student's t-test.
Results
Effect of In Vivo Treatment of F344 Rats with mAb 3.2.3 on NK Activity and ADCC of Fresh Spleen Cells andPBMC. We treated F344 rats with 100 141 of mAb 3.2.3 ascites intraperitoneally once a day for 3 d. 1 d later (on day 4) both NK and ADCC activities of PBMC and spleen cells were determined. Table I shows that NK and ADCC activity of fresh PBMC and spleen cells were virtually eliminated after treatment with mAb 3 .2 .3 . To study the dose dependence and kinetics of this effect, we treated rats with various amounts of mAb and measured NK activity of fresh spleen cells at different intervals after treatment . As shown in Fig . 1 , treatment for 3 d with 100 p.l mAb 3.2.3 ascites once a day could completely eliminate NK activity for >10 d. NK activity then returned to nearly control levels by day 19 . The depression in NK activity was dose dependent as both the absolute level of depression as well as the duration of depression were dependent on the quantity of ascites administered .
We also studied the effects of a single dose treatment with either 50 td or 100 pl (Fig. 2) .
To rule out that the NK depletion in vivo was caused by a nonspecific effect of the mAb 3.2.3 ascites fluid, we treated rats with different concentrations of affinitypurified antibody. Fig. 3 (Fig. 4) . Two-color FRCS analysis showed that half of these 3 .2.3(dim+) cells coexpressed CD5, indicating a T cell origin . Spleen cells from normal rats also contain a subpopulation of CD5+/ 3 .2.3(dim+) cells (-6%), and we found that these cells are CD8+ , CD2`and TCRa/a+ T cells that are not capable of lysing NK-sensitive targets or of ADCC even after 5 d ofculture with IL-2 (manuscript in preparation) . Interestingly, Fig. 5 also shows a small subpopulation (3.0%) of CD5 -/3.2.3(dim+) cells, which is present in spleen cells from 3.2 .3-treated rats, but not in spleen cells from normal rats . Further analysis of these CD5 -/3.2.3(dim+) cells in 3 .2 .3-depleted rats showed that these cells are CD2+, CD8+ (N50%), CD4-, TCRa/j3 -, and display less cytolytic activity against NK-sensitive targets than CD5 -/3. 3 . NK and ADCC activity in F344 rats treated with varying doses of affinitypurified mAb 3 .2 .3 or purified irrelevant IgG for two consecutive days. Splenic NK activity (E/T ratio 50:1) and ADCC (E/T ratio 50 :1) was determined 2 days later (day 4) . Each column represents mean NK or ADCC activity of two rats.
We also performed blood differential analysis on Giemsa-Wright-stained peripheral blood smears to determine if PMN, which express low levels of the antigen identified by mAb 3.2.3, are affected by treatment with mAb 3.2.3 ascites in vivo. Table IV shows that no significant differences in percentages or absolute numbers of PMNs, lymphocytes, or monocytes were noted after treatment with mAb 3.2.3. Also the percentage of immature PMNs with band-shaped nuclei was not changed. Similar results were obtained when animals were pretreated with 0.05 mg/ml affinity-purified mAb 3 .2 .3 and injected 1 d later with 0.5 x 106 MADB106 cells intravenously (Fig . 5 B) . In contrast, when 5 x 106 MADB106 cells were injected subcutaneously, no significant difference (p > 0.05) in tumor growth between the 3.2 .3-treated and control groups was noted at any time over a 30-d period ( Figure 6 ) . (21) also found similar correlation between a decrease in NK activity and a decrease in the number of LGL after treatment with anti-asialo GMi antibody.
In concordance with the depletion of NK/ADCC function and LGL, we also found quantitatively decreased expression of NK-associated surface markers (CD2, CD8, asialo GMI, and 3.2 .3) on spleen cells from 3.2.3-treated rats but no changes in surface markers not expressed on NK cells (CD5, CD4, OX41, and TCRado) . The remaining 3.2.3(dim+) cells in 3.2.3-treated rats were found by two-color FAGS analysis to contain CD5+ as well as CD5-cells. The CD5 + cells were unequivocally shown to be T cells as they also expressed the TCRcad3. The CD5-/3 .2.3(dim+) cells present in 3 .2.3-treated rats were found to coexpress CD2 and CD8 (N50%) but not CD5, CD4, or TCRa/(3. These cells showed less cytotoxicity against NK-sensitive targets than CD5 -/3.2.3 (bright+) cells and were not observed in normal F344 rats. They may represent either pre-NK cells, which appear in the spleens ofrats depleted of active NK cells due to an unknown regulatory mechanism, or mature NK cells with decreased cytolytic function due to in vivo binding of 3 .2 .3, possibly leading to receptor modulation and functional impairment .
In addition to depletion of NK/ADCC activity, almost no LGL could be detected in Giemsa-stained cytospins of spleen cells or PBMC from 3.2 .3-treated rats. The few remaining LGL after mAb 3.2.3 treatment were morphologically distinct from LGL observed in cytospin preparations from untreated rats. These cells were smaller in size and contained fewer and smaller granules (data not shown) . These cells could either represent CD5-/3.2.3(dim+) NK cells (as suggested above) or the CD5+/ 3 .2.3(dim+) T cells. Additional studies are currently in progress to determine these two possibilities.
The selective depletion of NK cells with mAb 3 .2.3 resulted in a decreased survival after intravenous injection ofMADB106 mammary adenocarcinoma cells. However, depletion of NK cells did not appear to influence the growth of MADB106 cells injected subcutaneously. Our findings with the growth of MADB106 intravenously or subcutaneously in NK-depleted animals support the results of other investigators that (a) NK cells are involved in the elimination of tumor cells in vivo (12) (13) (14) (15) , and (b) NK cells in vivo are less effective against subcutaneous growing tumors than against tumor metastases in visceral organs (22) .
In the past, various antibodies have been used to deplete NK cells in vivo. The first antiserum to be used for in vivo treatment of mice and rats was anti-asialo GMi . This is a rabbit antiserum that recognizes a glycosphingolipid, ganglio-N-tetraosylceramide (23) present on mouse (23, 24) , rat (25) , and human (7) NK cells. However, asialo GM, is not a specific marker for NK cells, since it has been found to be expressed on interstitial and alveolar lung macrophages (26, 27) , activated peritoneal macrophages (28, 29) , alloimmune cytotoxic T lymphocytes (30) , peripheral blood T cells (25) , and subpopulations of cells in thymus, bone marrow, and lymph nodes (31, 32) .
Treatment of mice or rats in vivo with anti-asialo GM, antisera can provide effective depletion of NK activity without significantly affecting the function of T and B lymphocytes (33, 34) . However, this is highly dosage dependent and high levels of anti-asialo GM, can also inhibit T cell functions (15). Habu et al. (33) showed that in anti-asialo GMi-treated nude mice the incidence of tumor take as well as tumor growth were enhanced when syngeneic (RLm-1), allogeneic (YAC-1), and human tumors were transplanted subcutaneously. Gorelik et al. (22) found that suppression of NK activity with anti-asialo GM, did not influence the growth of local tumors in C57BL/6 mice inoculated in the footpad with B16 melanoma or 3LL tumor cells, but accelerated the development of spontaneous pulmonary metastases . Also, the number of metastatic foci in the lungs of anti-asialo GMi-treated C57BL/6 mice increased 10 times after intravenous inoculation with B16 melanoma . Similar results have been observed by several other investigators (21, (35) (36) (37) (38) .
In addition to anti-asialo GMi, an NK-specific alloantiserum, anti-NK-1.1, can also be used to deplete mouse NK activity. Pollack and Hallenbeck (39) observed a reduced tumor clearance in lungs, liver, and spleen after treatment with anti-NK1 .1. Finally, the mAb OX8 (anti-C138), which recognizes cytotoxic/suppressor T cells, thymocytes, as well as NK cells in the rat, has been used in NK depletion studies (40, 41) . However, the disadvantages ofusing this mAb for depletion studies are obvious, since OX8 cannot distinguish cytotoxic/suppressor T cells from NK cells, and therefore, it does not allow a selective depletion of NK cells. Moreover, OX8 does not provide complete depression of NK activity in vivo (40, 41) .
The use of mAb 3 .2 .3 for in vivo NK depletion in rats is preferable to anti-asialo GMy or OX8 because of its strong and long-lasting effect and its high selectivity for NK cells. So far we have obtained complete NK depletion in various rat strains including Fischer 344, ACI, and Lewis (data not shown), suggesting that the NK depletion with mAb 3.2.3 is not strain dependent. We believe, therefore, that in vivo treatment of rats with mAb 3.2 .3 will be useful for studies on the functional role of NK cells in vivo, as well as their growth and differentiation from 3.2.3-precursors.
Summary
We recently described a mAb 3.2 .3 (IgGI), that recognizes a 60-kD dimeric molecule expressed exclusively on fresh and rIL-2-activated NK cells and polymorphonuclear cells (16) . mAb 3 .2.3 enhances cytolytic activity ofNK cells against selected FcR+ tumor target cells by reverse antibody-dependent cellular cytotoxicity (ADCC), indicating that it recognizes an important triggering site on NK cells. The in vivo treatment of F344 rats with mAb 3.2.3 intraperitoneally completely and selectively eliminated NK/ADCC function in the spleen and peripheral blood for up to 10 d after treatment. Total numbers and percentages of T cells, monocytes, or PMN were not decreased and T cell function, as determined by Con A stimulation, was not affected . The reduction in NK function was associated with a decrease in the numbers of LGL and the expression of other NK-related cell surface markers including CD2, CD8, and asialo GM, . Depletion of NK cells with 3.2.3 markedly decreased the survival of F344 rats injected intravenously with MADB106 mammary adenocarcinoma cells, but did not affect the subcutaneous growth ofMADB106 tumors. These results indicate that mAb 3.2.3 (in contrast to anti-asialo GM, and OX8, which are less selective markers) will be useful for studies on the functional role of NK cells in vivo as well as their in vivo differentiation and origin from 3.2 .3 -precursors.
